It refers to the compounds produced in the preparation process of dihydropyridine-3,5-diazo (I), wherein R1, R3, R4, R5 and AR1 are all defined in the description. [1 - [1 - (4) - [4] - [4] - [4) - [4 - [4 - [4]]]] - [er 3. Sulfur trifluoride-4 - (2-morfolin-4-iletoxi) phenyl) methyl] - 4-hydroxi-4a-meth-2-oxo-6, 7-dihydro-5h-pirolo [1, 2-B] piridazin-3-carboxamida；There are others He also mentioned a pharmaceutical composer These compounds are inhibitors of sodium phosphate transmitters for the treatment of hyperphosphate and chronic renal failure.SE REFIERE A COMPUESTOS DERIVADOS DE DIHIDROPIRIDAZIN-3,5-DIONA DE FORMULA (I) DONDE R1, R3, R4, R5 Y Ar1 SON TAL COMO SE DEFINE EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (4aR)-1-[(2,3-DIFLUOROFENIL)METIL]-4-HIDROXI-4a-METIL-2-OXO-N-[4-(TRIFLUOROMETIL)-2-[6-(TRIFLUOROMETIL)PIRIMIDIN-4-IL]FENIL]-6,7-DIHIDRO-5H-PIRROLO[1,2-b]PIRIDAZIN-3-CARBOXAMIDA； (4aR)-N-[2-(6-CIANO-5-METILPIRIMIDIN-4-IL)-4-(TRIFLUOROMETIL)FENIL]-1-[[2,3-DIFLUORO-4-(2-MORFOLIN-4-ILETOXI)FENIL]METIL]-4-HIDROXI-4a-METIL-2-OXO-6,7-DIHIDRO-5H-PIRROLO[1,2-b]PIRIDAZIN-3-CARBOXAMIDA； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE FOSFATO DEPENDIENTE DE SODIO SIENDO UTILES PARA EL TRATAMIENTO DE HIPERFOSFATEMIA, INSUFICIENCIA RENAL CRONICA
